Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and Foghorn's independent programs targeting CBP, EP300, and ARID1B.